<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386970</url>
  </required_header>
  <id_info>
    <org_study_id>04-1101</org_study_id>
    <secondary_id>R01AI064029</secondary_id>
    <nct_id>NCT01386970</nct_id>
  </id_info>
  <brief_title>Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics</brief_title>
  <official_title>Sex and Disease Dependent Nucleoside Analog Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the blood and blood cell concentrations of zidovudine and lamivudine in
      men versus women and in those with versus without HIV infection. Additionally, markers of
      side effects were correlated with blood levels of the drugs. The hypothesis was that women
      and those with HIV would have higher drug levels, as well as markers of side effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare zidovudine (ZDV)- and lamivudine (3TC)-triphosphate concentrations in women versus men.</measure>
    <time_frame>12 days</time_frame>
    <description>1st dose and day 12 dose compared after 12 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mitochondrial DNA before and after blood analysis</measure>
    <time_frame>day 12 (HIV negative) up to 2 years (HIV-infected)</time_frame>
    <description>To investigate relationships between ZDV- and 3TC-triphosphate concentrations and changes in mitochondrial DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate relationships between ZDV- and 3TC-triphosphate concentrations and the incidence of clinical side effects.</measure>
    <time_frame>day 12 (HIV-negative) various longer duration in times (HIV-infected)</time_frame>
    <description>To investigate relationships between ZDV- and 3TC-triphosphate concentrations and changes in mitochondrial DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug levels compared between HIV negative and HIV infected subject</measure>
    <time_frame>1st dose and day 12 dose</time_frame>
    <description>To compare ZDV- and 3TC- triphosphate concentrations in HIV-negative versus HIV-infected subjects.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>genetic associations with ZDV and 3TC disposition</measure>
    <time_frame>study time frame</time_frame>
    <description>Variability in genes encoding proteins influencing the disposition of ZDV and 3TC will be correlated with ZDV and 3TC disposition.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HIV-negative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine 300mg and lamivudine 150mg as Combivir</intervention_name>
    <description>twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group</description>
    <arm_group_label>HIV-negative</arm_group_label>
    <arm_group_label>HIV-infected</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented physician-diagnosed HIV-infection (HIV+ antibody or plasma HIV-RNA+);
             HIV-negative volunteers must have a negative HIV-ELISA.

          -  Age 18 to 55 years;

          -  Either antiretroviral na√Øve, or no HIV-therapy in the preceding 6 months;

          -  Planned antiretroviral regimen includes standard doses of ZDV plus 3TC as part of the
             antiretroviral regimen. Once- or twice-daily 3TC will be allowed.

        Exclusion Criteria:

          -  Any medical condition that in the opinion of the investigators would jeopardize the
             intent of the study.

          -  In the opinion of the investigator, any concomitant immunomodulatory medications,
             chemotherapeutic agents, investigational drugs, and alternative therapies, including,
             glucocorticoids, recombinant growth factors or cytokines (e.g. Granulocyte-macrophage
             colony-stimulating factor, Granulocyte colony-stimulating factor, interferon-alpha or
             gamma, human growth hormone, etc), ribavirin, birth-control pills, and sex hormones
             that could interfere with the cellular pharmacology of the study medications;

          -  Concomitant medications that interfere with renal drug clearances including,
             tenofovir, adefovir, cidofovir, ganciclovir, probenecid, or any similarly problematic
             medication in the opinion of the investigators;

          -  Concomitant warfarin or daily aspirin (to prevent excess bleeding from biopsy).

          -  Pregnancy or a plan to become pregnant, or menopause;

          -  Any &gt; or = grade II abnormality in hemoglobin, absolute neutrophil count, routine
             liver function tests, serum creatinine, or other organ function abnormalities.

          -  Any medical or personal condition that, in the judgment of the investigators, may
             influence the subject's ability to comply with study conditions, such as active mental
             illnesses, or plans to leave the geographical area.

          -  Inability to give informed consent.

          -  Triple nucleoside analog reverse transcriptase regimens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter L. Anderson, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Denver and Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver and Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anderson PL. Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. Curr Opin HIV AIDS. 2008 May;3(3):258-65. doi: 10.1097/COH.0b013e3282f85dc1.</citation>
    <PMID>19372976</PMID>
  </reference>
  <reference>
    <citation>Anderson PL, Rower JE. Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther. 2010;2:a2004.</citation>
    <PMID>20953318</PMID>
  </reference>
  <reference>
    <citation>Ghodke Y, Anderson PL, Sangkuhl K, Lamba J, Altman RB, Klein TE. PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics. 2012 Dec;22(12):891-4. doi: 10.1097/FPC.0b013e32835879a8.</citation>
    <PMID>22960662</PMID>
  </reference>
  <results_reference>
    <citation>Rower JE, Klein B, Bushman LR, Anderson PL. Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. Biomed Chromatogr. 2012 Jan;26(1):12-20. doi: 10.1002/bmc.1617. Epub 2011 Apr 4.</citation>
    <PMID>21465499</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, Gerber J, Fletcher CV. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS. 2007 Sep 12;21(14):1849-54.</citation>
    <PMID>17721092</PMID>
  </results_reference>
  <results_reference>
    <citation>Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, Klein B, Zheng JH, Mawhinney S, Anderson PL. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother. 2012 Jun;56(6):3011-9. doi: 10.1128/AAC.06337-11. Epub 2012 Mar 5.</citation>
    <PMID>22391541</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>nucleoside analogs</keyword>
  <keyword>mitochondrial toxicity</keyword>
  <keyword>clinical pharmacology</keyword>
  <keyword>cellular pharmacology</keyword>
  <keyword>pharmacogenetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

